We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I agree, be interesting and great if things comes off, not sure I can fix on a value at this time, there’s quite a few ifs and buts still to go. Gla
macnai - Wow. I'm not an accountant but I am very encouraged with the details to date. Roll on our listing and thank you for sharing.
5. An agreement dated October 15, 2019 the Company and Innovative Medicine Ltd. (“Innovative”) pursuant to which the Company agrees to provide advisory services to Innovative to enable a direct listing on the TSX-V in consideration for of an advisory fee of cash US$130,000 (approx. CAD$171,600) and the issue of US$900,000 in shares (approx. 6,000,000 shares) less than 20% of average trading price post admission in Innovative to the Company (“Advisory Shares”).
6. An agreement dated August 29, 2019, the Company and Innovative Medicine Ltd. (“Innovative”) pursuant to which the Company agrees to provide advisory services to Innovative to enable the establishment of a Luxembourg Securitisation company compartment specific use by Innovative to raise up to €90,000,000 with the first note raising €10,000,000 in consideration of an advisory fees to be satisfied by the issue of 30,000 Common Shares in Innovative to the Company (“Advisory Shares”), Euro €8.700 in cash and Securitisation compartment management fee of 4.2% of value of note issued for the life of the securitisation compartment and company. The Company is not conducting the capital raising rather by introduction to regulated sponsors. No commissions are being charged by the Company on any capital raisings. Each Luxembourg Securitisation companies has seven separate compartments to which a separate illiquid asset can be assigned.
7. An agreement dated October 15, 2019 the Company and Securlinx Biometrics Ltd. (“Securlinx”) pursuant to which the Company agrees to provide advisory services to Securlinx to enable a direct listing on the TSX-V in consideration for of an advisory fee of cash US$130,000 (approx. CAD$171,600) and the issue of US$900,000 in shares (approx. 6,000,000 shares) less than 20% of average trading price post admission in Innovative to the Company (“Advisory Shares”).
8. Escrow Agreement among the Issuer, Capital Transfer and Stuart J. Bromley, Robert Rhodes, Li Hongguang and Terence Larkan made as of August 28, 2019 referred to under “Escrowed Common Shares”.
9. On August 27 August 2019, the Company entered into a relationship agreement with Stuart J. Bromley whereby he agreed that all transactions and relationships between him and his affiliates on the one hand and the Company or any member of the Group on the other will be conducted on terms which allow the Company and the Group to carry on business independently, and all such transactions and relationships will be at arm’s length and on a normal commercial basis. Further he agreed not to exercise, and to procure that his affiliates did not exercise, any voting rights in relation to his interests in Common Shares. The agreement binds him for as long as he and his affiliates respectively together hold five (5) per cent. or more of the issued share capital of the Company.Ian